AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18326616 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone-enriched foods providing a mean daily intake of 110 mg isoflavone aglycones
Number of subjects: 237
Study 18326616 — intervention group
Group type: COMPARATOR
Intervention: Control products
Number of subjects: 237
Study 18326616 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone-enriched foods
Number of subjects: 237
Study 15528283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin A (CSA)
Number of subjects: 72
Study 15528283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 14740274 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (0.1 IU/kg)
Number of subjects: 20
Study 14740274 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin (0.1 IU/kg)
Number of subjects: 20
Study 14740274 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 20
Study 14740274 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 20
Study 14740274 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine and regular human insulin
Number of subjects: 20
Study 10755029 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced care and support
Number of subjects: 154
Study 10755029 — intervention group
Group type: COMPARATOR
Intervention: Regular health services
Number of subjects: 154
Study 8926224 — intervention group
Group type: EXPERIMENTAL
Intervention: Physically guiding the child to accept food contingent on noncompliance
Number of subjects: 3
Study 8926224 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonremoval of the spoon until the child accepted the presented food
Number of subjects: 3
Study 1299490 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (365 mg per day)
Number of subjects: 20
Study 1299490 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 20
Study 6493927 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective organization (free recall in any order)
Number of subjects: 60
Study 6493927 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimenter-presented order (recall from shortest to longest)
Number of subjects: 60
Study 6493927 — intervention group
Group type: COMPARATOR
Intervention: Forced-random group (recall in the same order as presented)
Number of subjects: 60
Study 30107419 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 1086
Study 30107419 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 1086
Study 30107419 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination nicotine patch and lozenge
Number of subjects: 1086
Study 30107419 — intervention group
Group type: COMPARATOR
Intervention: Patch monotherapy
Number of subjects: 1086
Study 29935535 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propacetamol followed by oral placebo
Number of subjects: 263
Study 29935535 — intervention group
Group type: COMPARATOR
Intervention: Oral dexibuprofen after intravenous 0.9% sodium chloride solution
Number of subjects: 263
Study 26864057 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Stability Exercise (CSE)
Number of subjects: 43
Study 26864057 — intervention group
Group type: COMPARATOR
Intervention: General Exercise (GE)
Number of subjects: 43
Study 25172878 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose PAZ320 (8 g)
Number of subjects: 24
Study 25172878 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose PAZ320 (16 g)
Number of subjects: 24
Study 22684202 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Dynamic Spine Stabilization Exercise Protocols (PDSSEP) - Thoracic Group
Number of subjects: 104
Study 22684202 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Dynamic Spine Stabilization Exercise Protocols (PDSSEP) - Cervical Group
Number of subjects: 104
Study 22684202 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 104
Study 20455890 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized GH treatment (17-100 microg/kg/day)
Number of subjects: 128
Study 20455890 — intervention group
Group type: COMPARATOR
Intervention: Standard GH dose treatment (43 microg/kg/day)
Number of subjects: 128
Study 20455890 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized GH treatment
Number of subjects: 128
Study 18592087 — intervention group
Group type: EXPERIMENTAL
Intervention: No-touch technique
Number of subjects: 156
Study 18592087 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 156
Study 18592087 — intervention group
Group type: COMPARATOR
Intervention: Intermediate technique
Number of subjects: 156
Study 17663377 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroidectomy with LigaSure
Number of subjects: 50
Study 17663377 — intervention group
Group type: COMPARATOR
Intervention: Traditional thyroidectomy
Number of subjects: 50
Study 12854177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sea buckthorn extract, 15 g 3 times a day for 6 months
Number of subjects: 50
Study 12854177 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B complex one tablet, 3 times a day for 6 months
Number of subjects: 50
Study 12854177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sea buckthorn extract
Number of subjects: 50
Study 10702196 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod, 2 mg twice daily for 1 week
Number of subjects: 24
Study 9337188 — intervention group
Group type: EXPERIMENTAL
Intervention: ELCA+PTCA
Number of subjects: 98
Study 9337188 — intervention group
Group type: COMPARATOR
Intervention: PTCA alone
Number of subjects: 98
Study 8225212 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.15 mg/kg, intravenously)
Number of subjects: 37
Study 8225212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 3981366 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation
Number of subjects: 30
Study 3981366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29478970 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 39
Study 29478970 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin plus GHR antagonist
Number of subjects: 39
Study 26679680 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 110
Study 26679680 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 110
Study 25437480 — intervention group
Group type: EXPERIMENTAL
Intervention: TECNIS Toric IOL
Number of subjects: 174
Study 23242398 — intervention group
Group type: EXPERIMENTAL
Intervention: Hua Oranga
Number of subjects: 172
Study 23242398 — intervention group
Group type: EXPERIMENTAL
Intervention: PCS (Physical Component Summary of SF36)
Number of subjects: 172
Study 20556256 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant placement
Number of subjects: 24
Study 20556256 — intervention group
Group type: COMPARATOR
Intervention: Delayed implant placement (ridge preservation with grafting)
Number of subjects: 24
Study 18854562 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrubicin (40 mg/m² on days 1-3)
Number of subjects: 60
Study 18854562 — intervention group
Group type: COMPARATOR
Intervention: Topotecan (1.0 mg/m² on days 1-5)
Number of subjects: 60
Study 18854562 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrubicin (in sensitive relapse)
Number of subjects: 60
Study 18854562 — intervention group
Group type: COMPARATOR
Intervention: Topotecan (in sensitive relapse)
Number of subjects: 60
Study 18854562 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrubicin (in refractory relapse)
Number of subjects: 60
Study 18854562 — intervention group
Group type: COMPARATOR
Intervention: Topotecan (in refractory relapse)
Number of subjects: 60
Study 18854562 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrubicin
Number of subjects: 60
Study 18854562 — intervention group
Group type: COMPARATOR
Intervention: Topotecan
Number of subjects: 60
Study 15699236 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl palmitate (850 microg retinol equivalents/d)
Number of subjects: 6
Study 15699236 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A-fortified rice (850 microg retinol equivalents/d)
Number of subjects: 6
Study 15699236 — intervention group
Group type: EXPERIMENTAL
Intervention: Goat liver (850 microg retinol equivalents/d)
Number of subjects: 6
Study 15699236 — intervention group
Group type: EXPERIMENTAL
Intervention: Amaranth leaves (850 microg retinol equivalents/d)
Number of subjects: 6
Study 15699236 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrots (850 microg retinol equivalents/d)
Number of subjects: 6
Study 15699236 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl palmitate (2000 microg retinol equivalents/d)
Number of subjects: 6
Study 15699236 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver (2000 microg retinol equivalents/d)
Number of subjects: 6
Study 15699236 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable groups (amaranth leaves, carrots)
Number of subjects: 6
Study 12731456 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 20 mg (E20)
Number of subjects: 1881
Study 12731456 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg (E10)
Number of subjects: 1881
Study 12731456 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg (L10)
Number of subjects: 1881
Study 12731456 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 1881
Study 10569660 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg/day) + placebo (E+P)
Number of subjects: 20
Study 10569660 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day) + placebo (L+P)
Number of subjects: 20
Study 10569660 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril + Losartan (E+L)
Number of subjects: 20
Study 10569660 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Placebo (P+P)
Number of subjects: 20
Study 8702449 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment counseling telephone intervention
Number of subjects: 405
Study 8702449 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom monitoring telephone intervention
Number of subjects: 405
Study 8702449 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 405
Study 1649715 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide (80 mg) administered 90 min before glucose clamp
Number of subjects: 8
Study 1649715 — intervention group
Group type: COMPARATOR
Intervention: Control (without gliclazide)
Number of subjects: 8
Study 6482180 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate hemodialysis under low-sodium conditions
Number of subjects: 12
Study 6482180 — intervention group
Group type: COMPARATOR
Intervention: Acetate hemodialysis under low-sodium conditions
Number of subjects: 12
Study 6482180 — intervention group
Group type: COMPARATOR
Intervention: Acetate hemodialysis under high-sodium conditions
Number of subjects: 12
Study 30447037 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 56
Study 30318893 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (average up to 115 mg in boluses of 20 mg) plus placebo (saline solution)
Number of subjects: 83
Study 30318893 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (3 mg) plus propofol (average up to 83 mg in boluses of 20 mg)
Number of subjects: 83
Study 27095338 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing and Cognitive Behavioral Therapy (MICBT) plus standard care
Number of subjects: 35
Study 27095338 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer term MICBT plus standard care
Number of subjects: 35
Study 27095338 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 35
Study 25429129 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted memory reactivation (TMR) of specific memory traces during slow-wave sleep
Number of subjects: 0
Study 25429129 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving TMR before sleep
Number of subjects: 0
Study 22759200 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic tacrolimus (Sandoz)
Number of subjects: 71
Study 22759200 — intervention group
Group type: COMPARATOR
Intervention: Reference tacrolimus (Prograf®)
Number of subjects: 71
Study 21162951 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet applied during total knee arthroplasty
Number of subjects: 60
Study 21162951 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tourniquet)
Number of subjects: 60
Study 17707851 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (0.1 microg/(kg min) for 24 hours, n=26)
Number of subjects: 39
Study 17707851 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=13)
Number of subjects: 39
Study 17707851 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 39
Study 17707851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 16809734 — intervention group
Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Number of subjects: 127
Study 16809734 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 127
Study 11893228 — intervention group
Group type: EXPERIMENTAL
Intervention: New antiepileptic drugs (AEDs)
Number of subjects: 0
Study 11893228 — intervention group
Group type: COMPARATOR
Intervention: Old antiepileptic drugs (AEDs)
Number of subjects: 0
Study 10458941 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing task (motor activation)
Number of subjects: 26
Study 10458941 — intervention group
Group type: COMPARATOR
Intervention: Supine resting state (control)
Number of subjects: 26
Study 7610938 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 20 mg
Number of subjects: 16
Study 7610938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2514782 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiramycin
Number of subjects: 55
Study 2514782 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V
Number of subjects: 55
Study 832830 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraeflux
Number of subjects: 32
Study 29784556 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical Turkish music
Number of subjects: 30
Study 29784556 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 30
Study 28240966 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (CBT)
Number of subjects: 169
Study 28240966 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 169
Study 24861978 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% autologous bone (Group A)
Number of subjects: 10
Study 24861978 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% porcine bone (Group B)
Number of subjects: 10
Study 24861978 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 : 50 mixture of autologous and porcine bone (Group C)
Number of subjects: 10
Study 23574990 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical music intervention (1 hour in the waiting area with classical music in the background)
Number of subjects: 169
Study 23574990 — intervention group
Group type: COMPARATOR
Intervention: Control group (1 hour with no music)
Number of subjects: 169
Study 23574990 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical music intervention
Number of subjects: 169
Study 21269858 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 60‐mg/kg dose of azithromycin extended‐release (ER)
Number of subjects: 0
Study 21269858 — intervention group
Group type: COMPARATOR
Intervention: 10‐day regimen of amoxicillin/clavulanate 90/6.4 mg/kg per day
Number of subjects: 0
Study 19384185 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) used as an early drug in a calcineurin inhibitor-free protocol in the first 3 months after transplantation
Number of subjects: 0
Study 19384185 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) used in early and late conversion protocols as suggested by the multicenter randomized CONVERT trial
Number of subjects: 0
Study 19384185 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) used in recipients from marginal donors
Number of subjects: 0
Study 16924010 — intervention group
Group type: EXPERIMENTAL
Intervention: IV immunoglobulin (IVIg) treatment
Number of subjects: 33
Study 15675752 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin prophylaxis
Number of subjects: 1226
Study 15675752 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 1226
Study 15675752 — intervention group
Group type: COMPARATOR
Intervention: Empirical therapy using benzylpenicillin in control group
Number of subjects: 1226
Study 15675752 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical therapy using benzylpenicillin in prophylaxis group
Number of subjects: 1226
Study 16403928 — intervention group
Group type: COMPARATOR
Intervention: Beta-blocker alone
Number of subjects: 412
Study 16403928 — intervention group
Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 412
Study 16403928 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone plus beta-blocker
Number of subjects: 412
Study 16403928 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone plus beta-blocker vs beta-blocker alone
Number of subjects: 412
Study 16403928 — intervention group
Group type: COMPARATOR
Intervention: Sotalol vs beta-blocker alone
Number of subjects: 412
Study 16403928 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone plus beta-blocker vs sotalol
Number of subjects: 412
Study 10319306 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrogel Vaginal (one applicator twice daily for five days)
Number of subjects: 60
Study 10319306 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (500 mg twice daily for seven days by mouth)
Number of subjects: 60
Study 7577275 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid preloading (1 litre lactated Ringer's)
Number of subjects: 26
Study 7577275 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid preloading (0.5 litre hydroxyethyl starch)
Number of subjects: 26
Study 7577275 — intervention group
Group type: COMPARATOR
Intervention: Both crystalloid and colloid preloading
Number of subjects: 26
Study 2023164 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20mg
Number of subjects: 0
Study 2023164 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 10mg
Number of subjects: 0
Study 2023164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6784566 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment (2%, 15 mg) administered every 6 hours for 48 hours
Number of subjects: 10
Study 6784566 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment administered every 6 hours for 48 hours
Number of subjects: 10
Study 30673620 — intervention group
Group type: EXPERIMENTAL
Intervention: High-accruing institutions (HAIs) (≥10 enrolled patients)
Number of subjects: 1252
Study 30673620 — intervention group
Group type: COMPARATOR
Intervention: Low-accruing institutions (LAIs) (≤ 9 enrolled patients)
Number of subjects: 1252
Study 29064909 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexacerfont (300, 200, and 100 mg/day in the first, second, and third week, respectively)
Number of subjects: 0
Study 29064909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29064909 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexacerfont
Number of subjects: 0
Study 26847973 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep problems at baseline
Number of subjects: 270
Study 26847973 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional problems at baseline
Number of subjects: 270
Study 26847973 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep problems and emotional problems from 6-12 months
Number of subjects: 270
Study 26847973 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep problems and conduct problems
Number of subjects: 270
Study 24468078 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous gel
Number of subjects: 95
Study 24468078 — intervention group
Group type: COMPARATOR
Intervention: Talcum powder
Number of subjects: 95
Study 22540391 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic endurance training, moderate intensity, supervised by a sport therapist, at least 3 times a week for 12 weeks.
Number of subjects: 60
Study 22540391 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training, Jacobson's progressive muscle relaxation, guided by a trained relaxation therapist, at least 3 times a week for 12 weeks.
Number of subjects: 60
Study 19939467 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried blood spots (DBS) from Guthrie cards
Number of subjects: 84
Study 19939467 — intervention group
Group type: COMPARATOR
Intervention: Blood samples from blood collecting tubes
Number of subjects: 84
Study 17414902 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention program for low back pain (LBP) in an occupational setting
Number of subjects: 489
Study 17414902 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 489
Study 16336673 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled dry powder mannitol (M)
Number of subjects: 592
Study 16336673 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic (4.5%) saline (HS)
Number of subjects: 592
Study 12020908 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar scissors tonsillectomy
Number of subjects: 50
Study 12020908 — intervention group
Group type: COMPARATOR
Intervention: Cold dissection tonsillectomy
Number of subjects: 50
Study 12020908 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall reactionary hemorrhage rate
Number of subjects: 50
Study 12020908 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall secondary hemorrhage rate
Number of subjects: 50
Study 12020908 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital readmission rate
Number of subjects: 50
Study 9633846 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (135 mg/m2, 24‐hour infusion) plus cisplatin (75 mg/m2)
Number of subjects: 0
Study 9633846 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m2, 3‐hour infusion) plus carboplatin dosed to an area under curve of 7.5
Number of subjects: 0